Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATRA plus GEMOX versus GEMOX alone for advanced intrahepatic cholangiocarcinoma
ChiCTR2000035434Phase 3Recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Aug 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tretinoin, gemcitabine and oxaliplatin in intrahepatic cholangiocarcinoma (ICC) (2 arms), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: overall survival. Started Aug 2020; status: recruiting.
02
Drugs
tretinoingemcitabineoxaliplatin
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on ChiCTR2000035434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000035434.